Charlotte Pain Management Center Celebrates Over 25 Years of Providing Relief
Charlotte Pain Management Center, known for its commitment to personalized pain treatment, celebrates over 25 years of delivering compassionate care and clinical excellence in Southwest Florida. Established in 1997, it has become a cornerstone of hope and healing for those dealing with chronic pain. Dedicated to restoring quality of life, it combines medical expertise, innovation, and patient advocacy.
'It's difficult to put into words what this milestone means to us,' says Nancy Harris, RN, founder and CEO of Charlotte Pain Management Center. 'Personally, this clinic isn't just a business. It's a calling. I grew up believing you help people whether you know them or not, and that principle has guided everything we do here. After so many years, to still be here and still making a difference, we're beyond grateful. Our patients trust us with some of the hardest parts of their lives, and that trust means everything to us.'
Charlotte Pain Management Center was founded on the belief that no one should have to live in persistent pain without access to meaningful relief. Catering to patients suffering from nerve pain, neuropathy, bone and joint issues, and complex chronic conditions, the clinic offers interventional and non-interventional treatment plans that are as individualized as the patients themselves. The center employs a whole-patient approach that blends cutting-edge and compassionate care. This is evident in its services, from spinal cord stimulation and radiofrequency ablation to advanced joint and nerve block injections.
The team at Charlotte Pain Management Center includes experienced physicians, medical professionals, and behavioral health specialists who collaborate to address the physical, emotional, and psychological aspects of pain. Besides its team of experts, the clinic is also known for its commitment to accessibility. It works with patients who may lack insurance or resources, ensuring that no one is turned away without options.
'Where others might only offer one-size-fits-all procedures, we build sustainable and personalized care paths,' Harris says. That reputation for providing relief where others couldn't have helped solidified the clinic as a vital resource in the region. However, it's worth noting that it took grit and resilience for Charlotte Pain Management Center to establish itself in the field.
The founder began her career managing home health services and medical practices, where she witnessed firsthand the gap in long-term, effective pain care. Her vision to create a more humane and more effective approach led to the founding of the center. Unfortunately, the founder faced some monumental challenges within her personal life.
Yet, even during the darkest times, Harris never considered closing the doors. Her connection to her patients and the knowledge that many had nowhere else to turn drove her to push forward. 'I couldn't let them down,' she recalls. 'We're often the last stop. Shutting down wasn't an option.'
Emerging from that period with renewed focus, Harris revitalized the clinic. She hired a new physician who brought fresh capabilities and advanced techniques to the team, reestablished essential services like cancer pain treatment, and invested in the latest technologies, including state-of-the-art C-arm imaging equipment. The center expanded its programs to include comprehensive neuropathy protocols and innovative, lesser-known modalities. The outcome was a rebirth both in operations and in mission.
As it celebrates over 25 years of serving the community, Charlotte Pain Management Center remains committed to staying at the forefront of the medical field. Harris remarks: 'Technology and treatments will continue to advance, but our priority will always be to deliver patient-centered care.'
Media Contact
Name: Nancy Harris, RN, BSN
Email: [email protected]
The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Reliance on any information provided in this article is solely at your own risk.
Source published by Submit Press Release >> Charlotte Pain Management Center Celebrates Over 25 Years of Providing Relief
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
24/7 Market News Issues Corrected Information on Previously issued Press Release with same title DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. 2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including a first trial result, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity. Upcoming Catalysts: Anticipated Trial Results in 2H 2025 1B/2 Trial – Ovarian Clear Cell Carcinoma (OCCC) Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5–10% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality. The Phase 1B/2 study of LB-100 plus the checkpoint inhibitor dostarlimab (GSK) is designed leverage LB-100's synergistic enhancement of immune checkpoint blockade. Status: Enrolled, with interim safety completed Upcoming Milestone: Preliminary safety and efficacy data expected Q4 2025 Potential Market Impact: Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies 1B/2 Trial – Advanced Soft Tissue Sarcoma (STS) Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains Phase 1B/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS. Status: Dose escalation completed. Upcoming Milestone: Safety report Q4 2025 Potential Market Impact: The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need 1B Trial – Metastatic Microsatellite Stable (MSS) Colon Cancer MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors. LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with+ atezolizumab (Roche) (an ICI), seeking to overcome immune resistance in this cold tumor type. Status: Trial open, first patients recruited Potential Market Impact: The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases Platform Potential and Market Opportunity LIXTE's strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform's potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence. Strong IP Position: Multiple issued and pending patents covering composition, methods of use, and combinations Pipeline Expansion: Additional tumor types and investigator-sponsored studies are under review, including glioblastoma. Partnership Potential: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities Contact sales@ for Analyst Report coverage and other investor/public relations services. About LIXTE Biotechnology Holdings, Inc. LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. More information can be found at: 24/7 MARKET NEWS, INC DisclaimerPlease go to for further LIXT information and LIXT disclosure information. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law. CONTACT: CONTACT: 24/7 Market News Editor@ in to access your portfolio
New York Times
31 minutes ago
- New York Times
Draft of White House Report Suggests Kennedy Won't Push Strict Pesticide Regulations
A highly anticipated White House report on the health of American children would stop short of proposing direct restrictions on ultraprocessed foods and pesticides, which the health secretary, Robert F. Kennedy Jr., has called major threats, according to a draft of the document that was reviewed by The New York Times. The report, if adopted, would be good news for the food and agriculture industries, which feared far more restrictive proposals than the ones outlined in the draft. Through his 'Make America Healthy Again' movement, Mr. Kennedy has sought to overhaul the nation's diet by pushing those industries to make major changes. The draft includes an array of policy proposals calling for research into topics like electromagnetic radiation, children's oral health, the role of the microbiome and the health effects of air quality and microplastics. It also recommends government action on a wide range of issues, including initiatives to increase breastfeeding rates, address infertility, promote physical activity and educate the public on the effects of vaping. Questions about a possible push for new pesticide regulations were raised in May when the White House released an initial report, from a presidential commission chaired by Mr. Kennedy, that raised strong concerns about possible links between pesticides and childhood diseases. It also linked the dominance of ultraprocessed foods in children's diets to a range of chronic diseases. Those findings touched off tensions between Mr. Kennedy's movement and Republican lawmakers who have traditionally drawn support from powerful agriculture, food and drug lobbyists. The Times obtained the draft of the new report from a former federal official. An industry official confirmed that it was nearly identical to a copy the administration had recently shown the official at the White House. Kush Desai, a White House spokesman, on Thursday would not verify the draft. At this stage, any draft would go through a number of revisions before it is finalized. The document The Times reviewed was labeled 'pre-decisional' and dated Aug. 6. Called the 'Make Our Children Healthy Again Strategy,' the report comes from the commission led by Mr. Kennedy, which includes cabinet secretaries and agency heads from across the government. The White House has not said when the report will be made public, though it was to have been presented to President Trump on Tuesday, the deadline set by Mr. Trump's executive order establishing the 'MAHA Commission.' The final report is expected to be released in the coming weeks. The draft report says that environmental regulators will work with 'food and agricultural stakeholders' to ensure that the public is aware of and confident in existing pesticide review procedures. It described those procedures as 'robust' and did not propose new restrictions. It also says the Trump administration will back research on technologies to try to help farmers reduce pesticide use and on the health effects of Americans' cumulative exposure to chemicals. After the first report was published in May, agriculture groups, including the American Soybean Association and the National Corn Growers Association, urged the Trump administration to listen to farmers as the commission prepared its follow-up report outlining a strategy. The draft reviewed by The Times does not mention how the proposed research and the new policy initiatives would be funded or how much money might be allocated to them. But it says that the Department of Health and Human Services will form a working group to evaluate 'overprescription trends' involving mental health medications, such as S.S.R.I.s and stimulants, for children. It reiterates Mr. Kennedy's pledge to study the 'root causes' of autism. Mr. Kennedy has spent much of his tenure as health secretary characterizing modern American childhood as a state of stress and sickness, with children mainly eating ultraprocessed food, which he has called 'poison,' tethered to screens and reliant on pills and shots. And he has railed against the pharmaceutical industry, which he says exerts undue influence over scientific research, all while the Trump administration has decimated funding for many academic research programs. Mr. Kennedy has also condemned scientific experts. In June, he fired all the members of an influential vaccine advisory panel. The first report, from May, reflected many of Mr. Kennedy's key talking points. It was heavily scrutinized. While some scientists applauded its focus on flaws within the American food system, many noted it misrepresented the scientific consensus on issues like vaccines. The report also cited studies that did not exist. In recent weeks, Mr. Kennedy's aides and allies have publicized what they described as the administration's most significant steps to improve American health. These include persuading some food makers to phase out petroleum-based food dyes, working with several states to remove soda and candy from their food stamp programs and trying to tighten oversight of food additives. The draft reiterates that the administration will continue these efforts. Some researchers have cautioned that such steps may not do much to improve the overall healthfulness of the American food supply. Ultraprocessed foods, which make up about 62 percent of the calories consumed by U.S. children, are explicitly mentioned in the draft of the second report only once, in a line about the administration's effort to define them. The near-omission of ultraprocessed foods from the draft report raises questions about the administration's appetite for regulation, which the food industry is likely to vehemently oppose. The draft does describe prioritizing 'whole, healthy' foods in federal programs like those providing meals in schools. It suggests offering these foods in 'MAHA boxes' for food stamp recipients. The draft touches on a number of other topics, including vaccines, a focus of Mr. Kennedy's. It says the health department will develop a framework for 'Ensuring America has the Best Childhood Vaccine Schedule.' Mr. Kennedy, one of the nation's most prominent vaccine skeptics, recently pledged to overhaul the nation's system to compensate people harmed by vaccines. Earlier this month, he canceled nearly $500 million in contracts for mRNA vaccines. The draft report also suggests that the government will consider developing guidelines that would limit marketing of unhealthy foods directly to children and will more vigorously enforce restrictions around direct-to-consumer drug advertising. It says the Centers for Disease Control and Prevention will update its recommendations on fluoride in water. On Tuesday, Calley Means, a senior adviser to Mr. Kennedy, spoke at a Heritage Foundation event on the role of agriculture in public health, presenting farmers as key players in American health care. 'We are not going to win if the soybean farmers and the corn growers are our enemy,' he said. There are signs that the report, as drafted, could land with a thud among Mr. Kennedy's followers. In July, 500 people, including leaders of advocacy groups aligned with Mr. Kennedy's movement, sent a letter to Mr. Kennedy and other members of the White House commission urging them to ban pesticides like glyphosate. Hundreds of people tied to the MAHA movement, including Vani Hari, a prominent food activist and MAHA influencer, also sent a letter addressed to Mr. Trump on Monday urging him to take action against protections for pesticide manufacturers. Over the first six months of his presidency, Mr. Trump has largely supported Mr. Kennedy's decisions, after urging him during the campaign to 'go wild' on health. This month, though, after Mr. Kennedy canceled the contracts for mRNA vaccines, Mr. Trump told reporters that the mRNA coronavirus vaccine development initiative from his first term, Project Warp Speed, was 'one of the most incredible things ever done in this country.' He said he had scheduled a meeting with Mr. Kennedy to discuss the cancellations. While Mr. Trump convened the commission, and put Mr. Kennedy at the helm, he does not have to follow its guidance. 'Unlike other administrations, we will not be silenced or intimidated by the corporate lobbyists or special interests,' Mr. Trump said in May during an event celebrating the release of the commission's first report. 'I want this group to do what they have to do.' 'In some cases, it won't be nice, or it won't be pretty,' he added, 'but we have to do it.'
Yahoo
33 minutes ago
- Yahoo
Bindi Irwin reveals major health update: 'Felt utterly ashamed'
Bindi Irwin has shared a major health update in her long battle with endometriosis. Taking to Instagram, the Wildlife Warrior shared a selfie, revealing she was "finally" feeling better after undergoing two major surgeries. "13 years of fighting for answers. 51 endometriosis lesions, a chocolate cyst, and my appendix were all removed across two surgeries with [Dr. Seckin]," she began her lengthy caption. "My hernia from giving birth that was unzipping - was taken care of. I can FINALLY say that I'm feeling better. Genuinely healing. I can function in everyday life without wanting to throw up or pass out from the pain. Slowly, slowly gaining my strength back." She continued, "I cannot express the gravity of my emotions as I am beginning to recognise myself again. I felt utterly ashamed as a teenager and young adult being told that my pain was just part of being a woman. I felt lesser. I felt hurt. I felt weak. That is not ok. "Young girls and women shouldn't feel alone with pain in the driver's seat of their lives. We need to take away the stigma of talking about women's health. It's time to have open discussions and make change on a global scale." RELATED: Bindi Irwin has fans in tears with emotional admission about Robert Irwin: 'Sobbing' Robert Irwin shares sweet tribute to sister Bindi Irwin after major surgery: 'Crippling' Bindi Irwin reveals she was 'really sick' for '10-plus years': 'Doctors didn't know' Bindi was previously forced to pull out of the Steve Irwin Gala in Las Vegas in May for surgery, leaving her brother Robert Irwin to host solo. At the time, Robert shared a tribute to his sister that read: "Happy to see you on the up and up, Bindi. You face every hurdle head on, take it in your stride and inspire us." Bindi commented on the post, "One day at a time. Tremendously grateful for your support. You're the best." Bindi Irwin's fans praise her bravery Fans commented on Bindi's post, sharing their admiration, with one person writing, "So proud of you for speaking up and sharing your journey." "I could not think of a better ambassador and role model for women going through this disease than you," another said. "So proud of you and excited for your new beginning, you have bloomed." "Thank you for sharing your story," a third wrote. "We need to keep advocating for every single person out there struggling & being dismissed!" "Thank you for all that you do to advocate for the endometriosis community!" someone else wrote. "You have brought so much awareness to this disease." "I am so sorry you struggled and were in pain," another said. "I am so happy you are healing. You are a very special soul - thank you so much for sharing your story and giving a voice to what affects so many women." Australia Zoo also commented, "Thank you Bindi for your strength and kindness in sharing your personal journey and thus allowing a light to shine on women's health! We LOVE that you are healing, and your bravery is encouraging others to speak out and seek answers." View this post on Instagram A post shared by Not Gonna Lie with Kylie Kelce (@nglwithkylie) What is endometriosis "Endometriosis is a disease in which tissue similar to the lining of the uterus grows outside the uterus," according to the World Health Organisation. "It can cause severe pain in the pelvis and make it harder to get pregnant. "Endometriosis can start at a person's first menstrual period and last until menopause. With endometriosis, tissue similar to the lining of the uterus grows outside the uterus. This leads to inflammation and scar tissue forming in the pelvic region and (rarely) elsewhere in the body." The cause of endometriosis is unknown, and unfortunately, there is no way to prevent it. There is also no cure, and it can only be treated with medication or surgery. Some people will not experience symptoms, but for those who do, it's often pain in the lower part of the belly. SHOP: 🏉 Rugby fan's huge airport surprise after landing in Sydney: 'Surreal' 🛏️ Expert reveals secret to the best night's sleep: 'Wouldn't choose anything else' 🦥 Boody's new range in sizes S to XL are 'the softest sets you'll ever wear': 'Comfy and chic' WHO adds, "It can decrease quality of life due to severe pain, fatigue, depression, anxiety and infertility. Some individuals with endometriosis experience debilitating pain that prevents them from going to work or school." Pain can also be noticeable during a period, during or after sex, or when going to the toilet. Some people also experience: chronic pelvic pain heavy bleeding during periods or between periods trouble getting pregnant bloating or nausea fatigue depression or anxiety Symptoms can improve after menopause, but not always.
